All In Biotech

Free tool

FAERS Monitor: Firazyr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022150 or its brand name (Firazyr, Icatibant Acetate). Reports on generic versions are filed under their own applications.

Reports

6,011

Serious

4,052

67% of reports

Hospitalization

2,349

Death reported

155

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hereditary angioedema2,634
  • drug ineffective504
  • product dose omission issue451
  • weight decreased415
  • weight increased379
  • injection site pain307
  • off label use277
  • product use issue275
  • inappropriate schedule of product administration243
  • headache234
  • stress217
  • condition aggravated203
  • malaise200
  • covid-19191
  • nausea182

Reports by year received

View as table
YearReports
20101
20114
201246
2013219
2014215
2015384
2016400
2017296
2018622
2019586
2020406
2021422
2022456
2023504
2024442
2025503
2026505

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hereditary angioedemaSignal2,6341137.51097.42,257,908
stressSignal21710.69.31,870
weight increasedSignal3795.95.41,563
product dose omission issueSignal4515.44.91,621
weight decreasedSignal4155.24.71,424
product use issueSignal2755.14.6916
inappropriate schedule of product administrationSignal2434.74.2715
covid-19Signal1913.83.3396
injection site painSignal3073.53.1555
condition aggravatedSignal2032.32.0156
malaise2001.61.445
drug ineffective5041.31.246
headache2341.31.217
off label use2771.11.03
nausea1820.80.79

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.